Savefor later Page saved! You can go back to this later in your Diabetes and Me Close

Tirzepatide can be prescribed on NHS in Scotland as treatment option for type 2 diabetes

doctor explains to patient

The Scottish Medicines Consortium (SMC) has accepted tirzepatide for use alongside diet and exercise to treat adults living with type 2 diabetes.

The Scottish Medicines Consortium (SMC) has accepted tirzepatide, which has the brand name Mounjaro, used alongside diet and exercise, to treat adults living with type 2 diabetes.

It can be used on its own, or alongside other medicines for treating type 2 diabetes.

SMC has accepted tirzepatide for restricted use. The restriction means that tirzepatide can be used to treat lower blood glucose levels in adults with type 2 diabetes, alongside other medicines used to treat diabetes when a type of medicine called a GLP-1 agonist would be considered.

John Kinnear, National Director, Diabetes Scotland, said:

“We welcome the Scottish Medicines Consortium’s decision to approve tirzepatide to be prescribed on the NHS as this will provide another effective treatment option for managing type 2 diabetes. It is very promising that the trial data showed great improvements in blood glucose management and weight loss.

“The current GLP-1 medication shortages are causing stress and uncertainty for many people with type 2 diabetes. While the approval of tirzepatide is welcome, we are calling for more action to ensure ongoing and sufficient supply of these medications to people with type 2 diabetes.” 

This document summarises the SMC decision and what it means for people living with diabetes.

Back to Top
Brand Icons/Telephonecheck - FontAwesomeicons/tickicons/uk